Aiming to Disrupt the NGS Market, Does Element Biosciences Hold Patents Strong Enough to Protect Itself From the Existing Market Leader?

felicewu
Tue, 26 Apr 2022 07:46:56 +0000
Case Studies and Portfolio Analyses, Biotech & Medicines, Due Diligence, Quality Insights

Key Points Founded by a trio of sequencing veterans from Illumina, Element Bio aims to change the current model of DNA sequencing service with its new benchtop NGS sequencer. Around 76% of Element Bio’s patent applications are pending. It’s still too early to draw conclusions about the overall quality of Element Bio’s patents. Illumina holds …